How do I pitch Community Health Media as a podcast guest?

Community Health Media has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.

Who is the host of Community Health Media?

Community Health Media is hosted by Unknown Host. The show is categorised under health (fitness) and has published 70 episodes.

How many episodes does Community Health Media have?

Community Health Media has published 70 episodes.

What topics does Community Health Media cover?

Community Health Media regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.

Is it hard to get booked on Community Health Media?

Community Health Media is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.

Is Community Health Media currently accepting guest pitches?

Community Health Media hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.

How long are Community Health Media episodes?

Episodes of Community Health Media average 40 minutes. a focused format where a clear narrative arc and tight preparation matter most.

What guest credentials does Community Health Media typically look for?

Our data rates Community Health Media's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.

health

Community Health Media

Hosted by Unknown Host · health · EN-US · 70 episodes

Apple Podcasts Website

About this Podcast:

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Pitch Analysis

Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.

Contact path

Verified email

Booking probability

33%

Guest openness

Selective

Verified email on file

80/100

Required Score

Signup to Generate a Pitch

What is Community Health Media?

Community Health Media is a health podcast hosted by Unknown Host, with 70 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

About the host

Unknown Host hosts Community Health Media, a health show with 70 episodes published.

Verified host email: ████████@████.comSign in to unlock →

Recent episodes

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

Community Health Media
This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran
Aug 13, 202625 min
Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC. The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with chemotherapy, with or without pembrolizumab depending on PD-L1 status. Dr. Damodaran also examines efficacy, toxicity, sequencing, and the practical tradeoffs that may influence which ADC clinicians choose. Topics discussed: Historical first-line treatment of metastatic TNBC TROPION-Breast02 and Dato-DXd ASCENT-03 and sacituzumab govitecan in PD-L1-negative disease ASCENT-04 and sacituzumab govitecan plus pembrolizumab Progression-free survival, overall survival, and response rates Toxicity differences between Dato-DXd and sacituzumab govitecan Stomatitis, ocular toxicity, neutropenia, and supportive care Whether TROP-2 expression should guide treatment BRCA mutations and where PARP inhibitors may still fit CNS activity and intracranial disease Choosing between Dato-DXd and sacituzumab govitecan ADCs sequencing The presentation concludes with a practical discussion on one of the biggest questions in TNBC today: If both ADCs are effective, how should clinicians choose between them? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care. Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #SenthilDamodaran #TripleNegativeBreastCancer #TNBC #ADC #DatoDXd #SacituzumabGovitecan #TROPIONBreast02 #ASCENT03 #ASCENT04 #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media
Listen Show Notes
Community Health Media
This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi
Aug 13, 202621 min
How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves? At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen. From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment based on disease biology, burden, toxicity, and patient preference. Topics discussed: The evolution of first-line HER2-positive metastatic breast cancer treatment CLEOPATRA and the foundation of modern HER2-directed therapy PATINA and the addition of palbociclib in HR+/HER2+ disease DESTINY-Breast09 and T-DXd plus pertuzumab Depth and duration of response with T-DXd HER2CLIMB-05 and tucatinib maintenance ILD, transaminitis, and other treatment-related toxicities Patient-reported outcomes and quality of life Selecting treatment based on ER status, CNS disease, disease burden, and molecular profile T-DXd duration and the possibility of induction-maintenance strategies How PATINA and HER2CLIMB-05 could inform maintenance therapy The presentation concludes with a panel discussion addressing a critical question for the field: With several highly effective strategies now available, how do we choose the right first-line approach for the right patient? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care. Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #MothaffarRimawi #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #PATINA #HER2CLIMB05 #BreastOncology #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media
Listen Show Notes
Community Health Media
This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo
Aug 13, 202625 min
Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings. From pathologic complete response and invasive disease-free survival to ILD risk and treatment sequencing, the presentation explores how clinicians might balance efficacy, toxicity, and individual recurrence risk as T-DXd moves into earlier-stage disease. Topics discussed: Current treatment for high-risk HER2-positive early breast cancer DESTINY-Breast11 and neoadjuvant T-DXd followed by THP Pathologic complete response and residual cancer burden DESTINY-Breast05 and T-DXd versus T-DM1 Invasive disease-free survival and emerging CNS outcomes ILD, nausea, cardiac safety, and treatment duration Neoadjuvant versus adjuvant use of T-DXd Whether THP alone may be sufficient for selected patients The potential role of ctDNA Where T-DM1 may still fit for residual disease Individualizing treatment according to recurrence risk The presentation concludes with a panel discussion exploring one of the biggest unanswered questions: How much T-DXd is enough—and when should it be used? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care. Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #MichelinaCairo #BreastCancer #HER2Positive #TDXd #TrastuzumabDeruxtecan #DESTINYBreast11 #DESTINYBreast05 #BreastOncology #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media
Listen Show Notes
Community Health Media
This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri
Aug 13, 202628 min
How is adjuvant treatment for ER-positive, HER2-negative breast cancer changing? At This Moment in Medicine, Dr. Akshjot Puri examines key data from OPTIMA, lidERA, NATALEE, and monarchE—and what these trials could mean for chemotherapy de-escalation, endocrine therapy, ovarian suppression, and CDK4/6 inhibitor use. From using Prosigna to identify patients who may be able to avoid chemotherapy to the emerging role of oral SERDs, the presentation highlights how treatment is becoming increasingly individualized based on risk, biology, and patient needs. Topics discussed: OPTIMA and Prosigna-guided chemotherapy de-escalation Chemotherapy benefit in premenopausal and postmenopausal patients The role of ovarian function suppression Oncotype DX, MammaPrint, and Prosigna lidERA and giredestrant in the adjuvant setting NATALEE vs. monarchE Ribociclib and abemaciclib in early-stage disease ctDNA and emerging biomarkers for treatment selection Individualizing therapy for intermediate- and high-risk patients ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care. Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #AkshjotPuri #BreastCancer #ERPositive #HER2Negative #OPTIMA #Prosigna #Giredestrant #NATALEE #MonarchE #BreastOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media
Listen Show Notes
Community Health Media
Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC
Jul 20, 202655 min
A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment.The conversation explores: Why DB09 may replace the CLEOPATRA standard The significance of 40+ month median PFS Complete response rates and treatment durability Managing ILD, fatigue, nausea, and alopecia Maintenance therapy strategies PATINA and HER2CLIMB-05 insights Sequencing after T-DXd progression Why “saving your best drug for later” may no longer apply This is a must-watch discussion on the evolving frontline landscape in HER2+ metastatic breast cancer.
Listen Show Notes

Advertisers on this show

Sponsor detection runs nightly. Check back soon.

Best industries to pitch Community Health Media for

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

healthstrong

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.

Podcasts like Community Health Media

All podcasts More health Top in US Top 100 by Booking Probability Booking Probability Index How scoring works How to get on podcasts

Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.

FAQs

Every question we get asked before
someone starts their trial.

If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.

What is the difference between Founder Solo and Founder Pro?

Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.

How do agency tiers work?

Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.

What is a talent profile?

A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.

Can I switch plans later?

Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.

Do you offer a free trial?

Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.

What happens if I cancel?

You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.

Is the 20% annual discount automatic?

Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.

What if I have more than 50 profiles or 20 clients?

That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.

Community Health Media

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

Aug 13, 202621 min

How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves? At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen. From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment based on disease biology, burden, toxicity, and patient preference. Topics discussed: The evolution of first-line HER2-positive metastatic breast cancer treatment CLEOPATRA and the foundation of modern HER2-directed therapy PATINA and the addition of palbociclib in HR+/HER2+ disease DESTINY-Breast09 and T-DXd plus pertuzumab Depth and duration of response with T-DXd HER2CLIMB-05 and tucatinib maintenance ILD, transaminitis, and other treatment-related toxicities Patient-reported outcomes and quality of life Selecting treatment based on ER status, CNS disease, disease burden, and molecular profile T-DXd duration and the possibility of induction-maintenance strategies How PATINA and HER2CLIMB-05 could inform maintenance therapy The presentation concludes with a panel discussion addressing a critical question for the field: With several highly effective strategies now available, how do we choose the right first-line approach for the right patient? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care. Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #MothaffarRimawi #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #PATINA #HER2CLIMB05 #BreastOncology #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Listen Show Notes

Every question we get asked before
someone starts their trial.

If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.

What is the difference between Founder Solo and Founder Pro?

How do agency tiers work?

What is a talent profile?

Can I switch plans later?

Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.

Do you offer a free trial?

Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.

What happens if I cancel?

You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.

Is the 20% annual discount automatic?

Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.

What if I have more than 50 profiles or 20 clients?

That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.

The platform

Free tools

By role

By need

Find shows

The data set

Live indexes

Browse by

Learn

Research & reads

Community Health Media

About this Podcast:

Pitch Analysis

What is Community Health Media?

About the host

Recent episodes

This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

Advertisers on this show

Best industries to pitch Community Health Media for

Podcasts like Community Health Media

Every question we get asked before
someone starts their trial.

Community Health Media

About this Podcast:

Pitch Analysis

What is Community Health Media?

About the host

Recent episodes

This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

Advertisers on this show

Best industries to pitch Community Health Media for

Podcasts like Community Health Media

Every question we get asked before
someone starts their trial.

Community Health Media

About this Podcast:

Pitch Analysis

What is Community Health Media?

About the host

Recent episodes

This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

Advertisers on this show

Best industries to pitch Community Health Media for

Podcasts like Community Health Media

Every question we get asked beforesomeone starts their trial.

Community Health Media

About this Podcast:

Pitch Analysis

What is Community Health Media?

About the host

Recent episodes

This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

Advertisers on this show

Best industries to pitch Community Health Media for

Podcasts like Community Health Media

Every question we get asked beforesomeone starts their trial.

Every question we get asked before
someone starts their trial.

Every question we get asked before
someone starts their trial.